-
公开(公告)号：US11460474B2
公开(公告)日：2022-10-04
申请号：US16257770
申请日：2019-01-25
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Hanspeter Brunner , Thomas Dieterle , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Andre Ziegler
IPC: G01N33/543 , G01N33/68 , A61K31/40 , G01N33/62
Abstract: The present disclosure is directed to a method of identifying a patient having heart failure as likely to respond to a therapy with a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein the patient has heart failure and undergoes a therapy with a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
-
公开(公告)号：US10942175B2
公开(公告)日：2021-03-09
申请号：US14549632
申请日：2014-11-21
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Ursula-Henrike Wienhues-Thelen , Dirk Block , Hendrik Huedig , Sabine Vogel-Ziebolz , Christine Boehm , Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC: G01N33/543 , G01N33/68
Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
-
公开(公告)号：US20200371114A1
公开(公告)日：2020-11-26
申请号：US16721112
申请日：2019-12-19
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Roberto Latini , Serge Masson , Dirk Block , Christian Zaugg , Thomas Dieterle , Edelgard Kaiser , Johann Karl , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen
IPC: G01N33/68
Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
-
公开(公告)号：US10557858B2
公开(公告)日：2020-02-11
申请号：US15581587
申请日：2017-04-28
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Roberto Latini , Serge Masson , Dirk Block , Christian Zaugg , Thomas Dieterle , Edelgard Kaiser , Johann Karl , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen
Abstract: Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.
-
公开(公告)号：US10345315B2
公开(公告)日：2019-07-09
申请号：US15274533
申请日：2016-09-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Johann Karl , Ursula-Henrike Wienhues-Thelen , Dirk Block , Christian Zaugg , Hans-Peter Brunner , James Januzzi , Andre Ziegler , Julian Braz , Thomas Dieterle , Edelgard Kaiser
Abstract: Disclosed herein is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Also disclosed is a method of monitoring diastolic function in a patient suffering from heart failure, and kits and devices for performing the method.
-
Patent Agency Ranking
公开(公告)号：US20150293122A1
公开(公告)日：2015-10-15
申请号：US14540165
申请日：2014-11-13
Inventor： Ursula-Henrike Wienhues-Thelen , Georg Hess , Hendrik Huedig , Herbert von der Eltz , Andrew Emili , Anthony Gramolini , Peter Liu , David MacLennan , Vincent Fong , Ruth Isserlin , Thomas Kislinger , Dirk Block
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N2333/47 , G01N2333/4727 , G01N2333/4737 , G01N2333/4745 , G01N2333/5412 , G01N2333/58 , G01N2800/325 , G01N2800/56
Abstract: The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
Abstract translation: 本发明涉及用于评估体外心脏衰竭的方法，包括以下步骤：在样品中测量标记物IGFBP-7的浓度，任选地在样品中测量一种或多种其他心力衰竭标志物的浓度， 并且通过比较在IGFBP-7中确定的浓度和为任选的一种或多种其它标记确定的浓度与在参考群体中确定的该标志物或这些标记的浓度进行比较来评估心力衰竭。 还公开了在评估心力衰竭中使用IGFBP-7作为标记蛋白，包括IGFBP-7的标记组合和用于测量IGFBP-7的试剂盒。
-
7.发明申请公开(公告)号：US20150233946A1
公开(公告)日：2015-08-20
申请号：US14705528
申请日：2015-05-06
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Roberto Latini , Serge Masson , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Andre Ziegler
IPC: G01N33/68
CPC classification number: G01N33/6887 , G01N33/6869 , G01N33/6893 , G01N2333/4712 , G01N2333/4737 , G01N2333/4745 , G01N2333/5412 , G01N2333/58 , G01N2800/326 , G01N2800/52
Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.
Abstract translation: 本发明涉及一种诊断近期阵发性房颤的方法。 该方法基于选自心肌肌钙蛋白，NT-proBNP（脑钠尿肽的N-末端激素原），hsCRP，IL-6（白细胞介素-6）和IGFBP7（ 来自受试者的样品中的胰岛素样生长因子结合蛋白7），以及由此确定的量与参考量（参考量）的比较。 此外，本发明涉及用抗凝治疗来鉴别受治疗者的方法。 进一步设想的是用于执行本文公开的方法的系统，试剂和试剂盒。
-
8.发明申请USE OF BIOMARKERS IN THE ASSESSMENT OF THE EARLY TRANSITION FROM ARTERIAL HYPERTENSION TO HEART FAILURE 审中-公开生物标记在评估从早期转移到心脏失效的早期转换中的应用公开(公告)号：US20150079615A1
公开(公告)日：2015-03-19
申请号：US14549632
申请日：2014-11-21
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Ursula-Henrike Wienhues-Thelen , Dirk Block , Hendrik Huedig , Sabine Vogel-Ziebolz , Christine Boehm , Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC: G01N33/543
CPC classification number: G01N33/54306 , G01N33/6887 , G01N33/6893 , G01N2333/4712 , G01N2333/495 , G01N2333/58 , G01N2800/325 , G01N2800/50 , G01N2800/52
Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
Abstract translation: 用于诊断心脏衰竭前的心脏的功能和/或结构异常以及用于预测心脏衰竭发展的风险的方法和系统，包括测量样品中的心肌肌钙蛋白并将测量值与参考值进行比较。 在一些实施方案中也测量了其它标志物，包括GDF15和IGFBP7。
-
公开(公告)号：US10684291B2
公开(公告)日：2020-06-16
申请号：US15220555
申请日：2016-07-27
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Hans-Peter Brunner , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Thomas Dieterle , Cheryl Mitchell , Johan Ubby , Sandra Sanders-van Wijk
Abstract: The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for optimizing B type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.
-
公开(公告)号：US20190277861A1
公开(公告)日：2019-09-12
申请号：US16420385
申请日：2019-05-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Johann Karl , Ursula-Henrike Wienhues-Thelen , Dirk Block , Christian Zaugg , Hans-Peter Brunner , James Januzzi , Andre Ziegler , Julian Braz , Thomas Dieterle , Edelgard Kaiser
IPC: G01N33/68
Abstract: The present disclosure relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.
-
-
-
-
-
-
-
-
-
Search Results
41
records
(took 0.033 seconds)
